| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | givastomig (bispecific Claudin 18.2 x 4-1BB antibody) Claudin 18.2-positive gastric cancers | Phase 2 | — | Biologics | Oncology | ||
phase 2 data readout example | givastomig (bispecific Claudin 18.2 x 4-1BB antibody) Claudin 18.2-positive gastric cancers | Phase 2 | — | Biologics | Oncology | ||
phase 2 data readout example | givastomig (bispecific Claudin 18.2 x 4-1BB antibody) Claudin 18.2-positive gastric cancers | Phase 2 | — | Biologics | Oncology |
Recent Updates
Recently added Catalysts
I-Mab Sponsored ADR$4.63
-0.07 (-1.49%)
C 54Pipeline Score Fair Value Pharma · Clinical
Market Cap
366.66 M
EPS
-
P/E Ratio
-
Value Trade
7.01 M
-9.22 %
Week
28.61 %
1 Month
128.08 %
3 Month
426.14 %
6 Month
-88.63 %
5 Year
-68.61 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.51 M
52 Week Range
0.60 - 6.79
% held by Insiders
16.33 %
% held by Institutions
22.89 %
Enterprise Value
204.53 M
Total Shares
79.19 M
Short %
4.31 %
Float Shares
63.68 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C54
Pipeline Score $783M
Pipeline ValueFair Value
Valuation Signal14
Drugs Scored2.1x
rNPV / MCap Top 83%
Micro Cap (rank 155 of 905)
Percentile RankI-Mab Sponsored ADR carries a moderate pipeline score (54/100), with $4.1B risk-adjusted pipeline value, led by TJ004309 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TJ004309 Small molecule | Ovarian Cancer | Phase 2 | NCT05001347 | 10% | $1.6B | COMPLETED | 25 | - | - | Feb 8, 2023 | - | Dec 16, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Givastomig | Metastatic gastric cancer,Gastroesophageal adenocarcinoma | Phase 1b | 2025-06-26 | |||
Givastomig | Metastatic gastric cancer,Gastroesophageal adenocarcinoma | Phase 1b | 2025-06-26 | |||
Givastomig | Metastatic gastric cancer,Gastroesophageal adenocarcinoma | Phase 1b | 2025-06-26 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMAB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IMAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How IMAB ranks across every disease it competes inCompetitive Position is a premium feature
See how IMAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial